EBITDA: Income before interest, taxes, depreciation and amortization.
Indaptus Therapeutics, Inc. (INDP) had EBITDA of $-8.16M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-8.11M |
|
-- |
|
-- |
|
$8.16M |
|
$-8.16M |
|
$0.04M |
|
$-8.11M |
|
$-8.11M |
|
$-8.11M |
|
$-8.11M |
|
$-8.11M |
|
$-8.11M |
|
$-8.16M |
|
|
EBITDA |
$-8.16M |
0.97M |
|
0.97M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$9.31M |
|
-- |
|
-- |
|
$9.31M |
|
$6.16M |
|
-- |
|
-- |
|
$6.16M |
|
$3.14M |
|
$3.15M |
|
$3.15M |
|
2.17M |
|
| Cash Flow Statement Financials | |
$-14.82M |
|
-- |
|
$17.54M |
|
$5.79M |
|
$8.51M |
|
$2.72M |
|
$1.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-258.23% |
|
-257.41% |
|
-87.14% |
|
-257.41% |
|
$1.45 |
|
$-15.34 |
|
$-15.34 |
|